Introduction
Preclinical and clinical evidence indicates that pharmacological concentrations of folates can potentiate the antineoplastic activity of 5-fluorouracil (1) . (67?,S')-Folinic acid, commercially available and used in all of the previous clinical trials, consists of an equimolar mixture of diastereoisomers. While the natural 6S isomer is rapidly metabolized in man, the unnatural 6R isomer is not metabolized and reaches high concentrations in plasma after i. v. administration of the mixture (2) . Intravenous administration of pure (65)-folinic acid resolves theoretical concerns over the effects of high concentrations of (6/?)-folinic acid. Therefore, an i.v. preparation of pure (65*)-folinic acid was developed. The pharmacokinetic studies of high dose continuous infusion (óSJ-folinic acid reported here were performed in association with a Phase I trial of high-dose (6S>folinic acid administered by continuous infusion throughout a 5-day course of bolus 5-fluorouracil.
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Materials and Methods
Patient eligibility and treatment plan
Patients with advanced cancer were entered in a Phase I study of bolus intravenous 5-fluorouracil at a dose of 370 mg/m 2 /day for 5 days combined with a continuous intravenous infusion of (óSj-folinic acid for 5.5 days, starting 24 h in advance of the first 5-fluorouracil dose. The dose of (6S)-folinic acid was escalated in cohorts of patients from 250 mg/m 2 /day to a maximum of 1000 mg m 2 day. All patients were over 18 years of age and gave written informed consent to participate. Details of the patient characteristics and the clinical results will be reported elsewhere.
Pharmacokinetics
Plasma and urine samples were obtained from 3 patients given 250 mg/m 2 /day of (6,S)-folinic acid and from 6 patients given 1000 mg/m 2 /day. The steadystate plasma concentrations (C ss ) of (öS^-folinic acid and 5-methyltetrahydrofolic acid [65")-CH 3 -THF] were estimated for individual patients by the mean concentrations of daily samples obtained between 23 and 119 h. Urine was collected during two 24 h periods beginning at least 23 h after the start of the infusion. To obtain pharmacokinetic parameters independent of a linear model, clearances were calculated in individual patients at steady-state using the following equations: Plasma clearance (CL P ) = dose rate/C 5S ; Renal clearance (CL r ) = amount excreted/ (plasma concentration χ 24 h); Non-renal clearance (CL nr ) = CLp -mean CL r . At steady-state the parameters are constant, although not predictive of the plasma concentrations at other times. Clearances were normalized based on each patient's body surface area. For comparison, pharmacokinetic parameters from a previously reported study of (6Ä,5')-folinic acid (2) were recalculated in a like manner, using only the data at steady-state. The procedures for sample processing and the determination of (6S')-folinic acid and (6S>CH 3 -THF by a combination of HPLC and microbiological assays are described elsewhere (2).
Results and Discussion
The unnatural isomer (6Ä)-folinic acid accumulates during i. v. infusion of (6i?,S>folinic acid (2). High concentrations of (6Ä)-folinic acid can interfere with the transport and metabolism of (65")-folinic acid, although recent evidence suggests that (67?)-ίο1ίηκ; acid may not interfere with the enhancement of 5-fluorouracil cytotoxicity by (6,5>)-folinic acid (3) . At the dose rate of 250 mg/m 2 /day, the C ss , CL P , CL r and CL nr of (6.S Y )-folinic acid (Table 1) were not significantly different from the results obtained during administration of (6Ä,5")-folinic acid [ Table 1 and (2)]. Hence, the presence of (6Ä)-folinic acid did not affect the pharmacokinetics of (6»S")-folinic acid in the earlier study.
The pharmacokinetic parameters at the low and high dose rates of (65")-folinic acid are compared in Table  1 . The pharmacokinetics were not linear over the dose range tested. The C ss of the parent drug (6S')-folinic acid increased more than 4-fold with a 4-fold increase in the dose, while the C ss of its principle circulating metabolite (6iS)-CH 3 -THF increased less than 4-fold. In accord with the greater than expected increase in the C ss of (öS^-folinic acid at the higher dose, its CL P was significantly lower at the high dose than at the low dose. The change in the CL P was accounted for by a significant decrease in the CL llr , while the change in the CL r between the two doses was not statistically significant and was in the wrong direction to account for the decrease in the CL P . The lower relative concentration of (6,S)-CH3-THF at the higher dose of (óS^-folinic acid suggested that saturation of the metabolism of (65")-folinic acid was responsible for the decrease in its CL nr . Transport of the substrate, several enzymatic steps, and transport of the product intervene between the disappearance of (6S')-folinic acid from the plasma and the appearance of (ó.S^-CH,-THF in the plasma. Plasma pharmacokinetics alone cannot identify the step at which saturation occurred. Quantitation of intracellular metabolites or minor metabolites in the plasma would be of benefit in identifying the site of saturation.
